June 19th 2023
Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.
March 13th 2023
The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.
Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.
March 6th 2023
Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.
Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.
February 27th 2023
Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.
Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.
February 20th 2023
Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.
Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.
February 13th 2023
The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.
Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.
February 6th 2023
Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.
The panel debates the options for treatment of late relapsed multiple myeloma.
January 30th 2023
Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.
Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.
January 23rd 2023
Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.
Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.
January 17th 2023
The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.
Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.